A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients

耐受性 医学 内科学 药代动力学 药效学 不利影响 实体瘤疗效评价标准 肿瘤科 临床试验 临床研究阶段 药理学 胃肠病学
作者
Kenneth Sooi,Tuan Zea Tan,Jae‐Weon Kim,Jung Y. Lee,Byoung-Gie Kim,David Micklem,Akil Jackson,David J. Pinato,Charlie Gourley,Rebecca Kristeleit,Sarah P. Blagden,Line Bjørge,David S.P. Tan
出处
期刊:British Journal of Cancer [Springer Nature]
卷期号:133 (6): 896-908 被引量:2
标识
DOI:10.1038/s41416-025-03090-6
摘要

BACKGROUND: Tilvestamab is a highly selective humanised immunoglobulin G1 anti-AXL monoclonal antibody. This phase 1 study evaluated its optimal dose, safety, tolerability, immunogenicity and pharmacokinetics (PK) in relapsed platinum-resistant HGSOC patients. METHODS: Patients received tilvestamab in three dose levels (1 mg/kg, 3 mg/kg and 5 mg/kg) via IV infusion every 2 weeks. Primary objectives included safety, tolerability and PK. Exploratory objectives included overall response, progression-free survival (PFS) and quality-of-life measures. Pharmacodynamic included AXL expression, gene and protein changes by transcriptomic and proteomic analysis. RESULTS: Between 25 February 2021 and 4 February 2022, 16 patients were enroled across 8 sites in Singapore, Korea, United Kingdom, and Norway. Median treatment duration was 6.1 weeks. Grade 3 or higher treatment-emergent adverse events occurred in 62.5% patients, but none were tilvestamab-related. Common events included fatigue (38%), anorexia (38%) infections (31%), anaemia (25%) and dyspnoea (25%). No objective responses were observed, but 7 (44%) had stable disease at 6 weeks. PK showed dose-proportional exposure and steady-state by the second dose. Pharmacodynamic analyses revealed reduced fibrosis-related gene signatures and AXL protein expression. Epithelial-mesenchymal transition reversal was seen in 2 patients. CONCLUSION: Tilvestamab was well-tolerated and further studies to examine the efficacy of AXL inhibition in other indications are required. CLINICAL TRIAL REGISTRATION: This trial is registered at https://clinicaltrials.gov . REGISTRATION NUMBER: NCT04893551. EudraCT Number: 2020-001382-36.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FashionBoy的应助被默默的河马采纳,获得10
刚刚
完美世界的应助被Hannipham采纳,获得10
1秒前
xr发布了新的文献求助10
1秒前
2秒前
2秒前
今后的应助被开心德地采纳,获得10
3秒前
3秒前
秋风的应助被小纪采纳,获得10
4秒前
4秒前
4秒前
5秒前
roro完成签到 ,获得积分10
5秒前
7秒前
7秒前
7秒前
顾矜的应助被RS采纳,获得10
9秒前
wg发布了新的文献求助10
9秒前
能干的人发布了新的文献求助30
9秒前
完美世界的应助被开心德地采纳,获得10
9秒前
HouShipeng发布了新的文献求助10
9秒前
9秒前
sinalpha10完成签到,获得积分20
10秒前
xr完成签到,获得积分10
10秒前
10秒前
10秒前
小蘑菇的应助被烂漫的诗双采纳,获得10
11秒前
香香鱼丸完成签到,获得积分10
11秒前
桴子完成签到,获得积分10
12秒前
SciGPT的应助被幸运周周周采纳,获得10
13秒前
13秒前
14秒前
16秒前
17秒前
17秒前
17秒前
小二郎的应助被qingshan采纳,获得10
17秒前
胖球球发布了新的文献求助10
18秒前
YanuoK发布了新的文献求助10
18秒前
啊呦阿柚完成签到,获得积分10
19秒前
zzyyqq发布了新的文献求助150
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188371
求助须知:如何正确求助?哪些是违规求助? 9576179
关于积分的说明 21845965
捐赠科研通 7786421
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559601
邀请新用户注册赠送积分活动 2482276